CLAIMS

What is claimed is:

1. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein the effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is given at least 1 hour or at least 2 hours before and/or after taking a second pharmaceutical composition comprising multivalent cations to increase or maintain bioavailability of {[5-(3-chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino}acetic acid (Compound **1**).

2. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject

wherein the effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is given at least 1 hour or at least 2 hours before and/or after taking a second pharmaceutical composition comprising multivalent cations to minimize, prevent or control a decrease in absorption of {[5-(3-chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino}acetic acid (Compound **1**).

3. The use of claims 1 or 2, wherein the second pharmaceutical composition is a calcium-containing composition, magnesium-containing composition, iron-containing composition, lanthanum-containing composition, or aluminum-containing composition.

4. The use of any one of claims 1–3, wherein the second pharmaceutical composition is iron-containing composition comprises one or more of ferrous sulfate, sodium ferrous citrate, ferric citrate, sucroferric oxyhydroxide, oral iron or an iron-containing phosphorus adsorbent.

5. The use of claim 4, wherein the iron-containing composition is to be administered as a tablet.

6. The use of any one of claims 1-3, wherein the second pharmaceutical composition is a calcium-containing composition comprising oral calcium acetate or calcium carbonate.

7. The use of any one of claims 1-3, wherein the second pharmaceutical composition is a lanthanum-containing composition, a magnesium-containing composition, or an aluminum-containing composition.

8. The use of claim 7, wherein the lanthanum-containing composition is an oral lanthanum carbonate.

9. The use of any one of claims 1–8, wherein {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be given at least 2 hours before and/or administration of the second pharmaceutical composition.

10. The use of any one of claims 1-8, wherein {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be given at least 1 hour before administration of the second pharmaceutical composition.

11. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**)or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein bioavailability of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be maintained in a subject when the subject is receiving a statin drug;

wherein amount of the statin drug is to be adjusted compared to an amount when the statin drug is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

12. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**)or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein an increase in exposure to {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the subject is to be minimized, prevented, or controlled when the subject is receiving a statin drug;

wherein amount of the statin drug is to be adjusted compared to an amount when the statin drug is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

13. The use of claims 11 or 12, wherein the subject is at risk of or has cardiovascular disease or diabetes, or has dyslipidemia.

14. The use of any one of claims 11-13, wherein the statin drug is simvastatin, pitavastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or atorvastatin.

15. The use of any one of claims 11-14, wherein the amount of the statin drug is to be decreased when compared to the amount when the statin drug is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

16. The use of claim 15, wherein the amount of the statin drug is to be decreased by about 20% to about 80% when compared to the amount when the statin drug is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

17. The use of any one of claims 11-16, wherein the statin drug is atorvastatin, or to one or more metabolites of atorvastatin.

18. The use of any one of claims 11-16, wherein the statin drug is rosuvastatin, and the dose is to be decreased by at least about 5, or 10 mg.

19. The use of any one of claims 11-16, wherein the statin drug is simvastatin, or to one or more metabolites of simvastatin, and the dose is to be decreased by at least about 5, 10, or 20 mg.

20. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein bioavailability of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be maintained in a subject when the subject is receiving an anti-inflammatory drug;

wherein amount of the anti-inflammatory drug is to be adjusted compared to an amount when the anti-inflammatory drug is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

21. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein an increase in exposure to {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the subject is to be minimized, prevented, or controlled when the subject is receiving an anti-inflammatory drug;

wherein amount of the anti-inflammatory drug is to be adjusted compared to an amount when the anti-inflammatory drug is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

22. The use of claims 20 or 21, wherein the anti-inflammatory drug is sulfasalazine, or to one or more metabolites of sulfasalazine

23. The use of any one of claims 20-22, wherein the subject is at risk of or has ulcerative colitis, Crohn's disease, or rheumatoid arthritis.

24. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein bioavailability of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be maintained in a subject when the subject is receiving a diuretic;

wherein amount of the diuretic is to be adjusted compared to an amount when the diuretic is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

25. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein an increase in exposure to {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the subject is to be minimized, prevented, or controlled when the subject is receiving a diuretic;

wherein amount of the diuretic is to be adjusted compared to an amount when the diuretic is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

26. The use of claims 24 or 25, wherein the diuretic is furosemide.

27. The use of any one of claims 24-26, wherein the subject is at risk of or has edema, has cardiovascular disease or liver disease.

28. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject with hepatic impairment.

29. The use of claim 28, wherein the hepatic impairment is mild or moderate hepatic impairment, or is characterized as Child Pugh Class B (7-9 points).

30. The use of claims 28 or 29, wherein the hepatic impairment is characterized by elevated bilirubin levels, decreased serum albumin levels, elevated international normalized ratios (INR), ascites, and/or hepatic encephalopathy.

31. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein bioavailability of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be maintained in a subject when the subject is receiving a BCRP (breast cancer resistance protein) substrate;

wherein amount of BCRP (breast cancer resistance protein) substrate is to be adjusted compared to an amount when the BCRP (breast cancer resistance protein) substrate is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

32. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in

the manufacture of a medicament for treating renal anemia (anemia secondary to or associated with chronic kidney disease) in a subject,

wherein an increase in exposure to {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the subject is to be minimized, prevented, or controlled when the subject is receiving a BCRP (breast cancer resistance protein) substrate;

wherein amount of the BCRP (breast cancer resistance protein) substrate is to be adjusted compared to an amount when the BCRP (breast cancer resistance protein) substrate is to be administered in the absence of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof or in monotherapy.

33. The use of claims 31 or 32, wherein the BCRP (breast cancer resistance protein) substrate is mitoxantrone, imatinib, irinotecan, lapatinib, apixaban, atorvastatin, baricitinib, copanlisib, dolutegravir, eltrombopag, ethinylertradiol, glecaprevir, glyburide, letermovir, methotrexate, paritaprevir, pibrentasvir, pravastatin, presatovir, prucalopride, rosuvastatin, simvastatin, sofosbuvir, sulfasalazine, tenofovir, topotecan, velpatasvir, venetoclax, or voxilaprevir.

34. The use of any one of claims 11-27, or 31-33, wherein the statin drug, anti-inflammatory drug, diuretic or BCRP (breast cancer resistance protein) substrate is to be administered or not to be administered simultaneously with {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof.

35. The use of any one of claims 1-34, wherein the chronic kidney disease is dialysis-dependent chronic kidney disease (DD-CKD) or non dialysis-dependent chronic kidney disease (NDD-CKD).

36. The use of any one of claims 1-35, wherein the subject is to be administered a daily dose of about 150-600 mg of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof.